innovating glioma therapy using secretions from umbilical cord mesenchymal stem cells to target homeobox and growth factor genes

Background: glioblastoma is a prevalent and challenging malignant brain tumor. secretome therapy using human umbilical cord mesenchymal stem cells (hucmscs) appears to be a promising treatment for glioblastoma. this study analyzed the potential of the hucmsc secretomes (hucmscs-sec) for glioma therapy.materials and methods: characterization of hucmscs was performed by examining certain markers, including cd44, cd90, cd105, cd73, cd13, cd19, cd14, cd45, cd34, and hla-d. the cells' ability to differentiate into adipocytes, chondrocytes, and osteocytes was evaluated. cytotoxic effect on glioblastoma (gbm) cells was analyzed using 2-[2-methoxy-4-nitrophenyl]-3-[4-nitrophenyl]-5-[2,4-disulfophenyl]-2h-tetrazolium (wst-8). mrna relative expression, including homeobox (hoxa5, hoxb1, hoxc9 and hoxc10), insulin-like growth factor binding protein 2 (igfbp2), extracellular signal-regulated kinases (erk), epidermal growth factor receptor (egfr), and caspase 3 (casp3), were quantified by quantitative reverse transcription polymerase chain reaction (qrt-pcr).results: the hucmscs-sec was successfully isolated and identified, showing positive markers and its capacity to differentiate into chondrocytes, adipocytes, and osteocytes. hucmscs-sec exerted a cytotoxic effect on gbm cells and upregulated the expression of casp3, whereas it decreased the expression of hox, igfbp2, egfr, and erk in gbm cells.conclusion: the secretomes from hucmscs show potential for gbm cell therapy by improving the deregulation of hox, inducing apoptosis, and inhibiting cell proliferation genes.